Status:
COMPLETED
Efficacy of Albuterol in the Treatment of Congenital Myasthenic Syndromes
Lead Sponsor:
Mayo Clinic
Conditions:
Congenital Myasthenic Syndrome
Eligibility:
All Genders
2+ years
Phase:
PHASE1
Brief Summary
The study tests the notion that patients suffering from certain types of congenital myasthenic syndromes are benefitted by the use of Albuterol at doses used in clinical practice.
Detailed Description
The aim of the proposal is to evaluate the effects of albuterol, an adrenergic agonist, in the treatment of congenital myasthenic syndromes (CMS). Over the past 2 decades I found that some CMS patient...
Eligibility Criteria
Inclusion
- Diagnosis of congenital myasthenic syndrome substantiated by typical clinical history, seronegativity to AChR and MuSK, and evidence of a decremental EMG response.
Exclusion
- Uncontrolled hypertension, arrhythmias, or other significant cardiac disease.
Key Trial Info
Start Date :
September 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2013
Estimated Enrollment :
21 Patients enrolled
Trial Details
Trial ID
NCT01203592
Start Date
September 1 2010
End Date
August 1 2013
Last Update
January 1 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mayo Clinic
Rochester, Minnesota, United States, 55905